Table 1.
Features of CMY-2-producing E. coli recovered from non-clinical origins in Portugal.
| Origin (Sample) a | Year of Collection | PhG b | ST/CC/PFGE-Type c | Genetic Environment of blaCMY-2 | Plasmid Replicon Content [Inc Family (Size in kb)] | Resistance to Non-β-Lactams f | |
|---|---|---|---|---|---|---|---|
| Associated with blaCMY-2 |
Other | ||||||
| HH (33) | 2014 | B22 | ST4953/EC2 | ΔISEcp1-blaCMY-2-blc-sugE | ND d | FII + I1 | GEN, NET, TOB, STR, TET, CHL, NAL, CIP, SUL |
| HH (34) | 2014 | B22 | ST4953/EC2 | ΔISEcp1-blaCMY-2-blc-sugE | ND d | FII | GEN, NET, TOB, STR, TET, CHL, NAL, CIP, SUL |
| HH (97) | 2014 | A0 | ST665/EC3 | ISEcp1-blaCMY-2-blc-sugE | NT e (75) | K + B/O | STR, TET, NAL, SUL |
| UCC (6) | 2003 | A1 | ST48/CC10/EC4 | ISEcp1-blaCMY-2-blc-sugE | A/C2 (150) | - | KAN, GEN, TOB, STR, TET, CHL, SUL |
a HH, healthy humans; UCC, uncooked chicken carcass; b PhG, E. coli phylogenetic group; c ST, Sequence Type, CC, clonal complex; d ND, not determined due to multiple plug degradations; e NT, non-typeable; f CIP, ciprofloxacin; CHL, chloramphenicol; GEN, gentamicin; KAN, kanamycin; NAL, nalidixic acid; NET, netilmicin; STR, streptomycin; SUL, sulphonamides; TET, tetracycline; TOB, tobramycin.